An assessment of the impact of herb-drug combinations used by cancer patients

BMC Complementary and Alternative Medicine

Volumn 16, Issue 1, 2016, Pages

  Alsanad, Saud M ^a   Howard, Rachel L ^b   Williamson, Elizabeth M ^b  

^a AL IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY IMSIU   (Saudi Arabia)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Alternative medicines; Cancer; Complementary medicines; Conventional medicines; Dietary supplements; Herb drug interactions; Herbal medicines

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMLODIPINE; ANTINEOPLASTIC AGENT; ATORVASTATIN; CLOPIDOGREL; COCODAMOL; COD LIVER OIL; DALTEPARIN; DIPYRIDAMOLE; DOXORUBICIN; EPIRUBICIN; FISH OIL; GLUCOSAMINE; HEPARIN; ICOSAPENTAENOIC ACID; INSULIN; LISINOPRIL; OMEGA 3 FATTY ACID; OMEPRAZOLE; PARACETAMOL; PRAVASTATIN; PRIMROSE OIL; RISPERIDONE; SELENIUM; SERTRALINE; SIMVASTATIN; UNINDEXED DRUG; VITAMIN; WARFARIN; PLANT MEDICINAL PRODUCT;

ADULT; AGED; ALLOPATHY; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; DRUG SAFETY; DRUG USE; FEMALE; GARLIC; GINKGO BILOBA; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; PALLIATIVE THERAPY; PATIENT PREFERENCE; PROSTATE CANCER; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; TEA; TREATMENT OUTCOME; UNITED KINGDOM; CHEMISTRY; NEOPLASMS; PHYTOTHERAPY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84992455930     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-016-1372-x     Document Type: Article

References (37)

1. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther. 2002;27:391-401.
2. Afifi FU, Wazaify M, Jabr M, Treish E. The use of herbal preparations as complementary and alternative medicine (CAM) in a sample of patients with cancer in Jordan. Complement Ther Clin Pract. 2010;16:208-12.
3. Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement-drug interactions: a systematic review. Phytother Res. 2014;28:1749-55.
4. Champy P, Melot A, Guérineau Eng V, Gleye C, Fall D, Höglinger GU, Ruberg M, Lannuzel A, Laprévote O, Laurens A, Hocquemiller R. Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in Guadeloupe. Mov Disord. 2005;20:1629-33.
5. Chrystal K, Allan S, Forgeson G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. NZ Med J. 2003;116:875-903.
6. Cui Y, Shu XO, Gao Y, Wen W, Ruan ZX, Jin F, Zheng W. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 2004;85:263-70.
7. Ernst E. The current position of complementary/alternative medicine in cancer. Eur J Cancer. 2003;39:2273-7.
8. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther. 2009;8:29-36.
9. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001;52:587-95.
10. Goey A, Beijnen J, Schellens J. Herb-Drug Interactions in Oncology. Clin Pharmacol Ther. 2014;95:354-5.
11. Gratus C, Damery S, Wilson S, Warmington S, Routledge P, Grieve R, Steven N, Jones J, Greenfield S. The use of herbal medicines by people with cancer in the UK: a systematic review of the literature. QJM. 2009;102:831-42.
12. Heinrich M, Barnes J, Gibbons S, Williamson EM. Fundamentals of Pharmacognosy and Phytotherapy. 2012. Elsevier Health Sciences.
13. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012;78(13):1458-77.
14. Hübner J. Complementary and alternative medicine in oncology. Versicherungsmedizin. 2013;65:79-83.
15. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract. 2012;21:404-28.
16. Izzo AA, Kim SH, Radhakrishnan R, Williamson EM. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of commonly used herbal remedies. Phytother Res. 2016;30:691-700.
17. Kelber O, Nieber K, Kraft K. Valerian: no evidence for clinically relevant interactions. Evid Based Complement Alternat Med. 2014;2014:879396.
18. Lee AH, Ingraham SE, Kopp M, Foraida MI, Jazieh AR. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol. 2006;29:178-82.
19. Mathijssen RH, Verweij J, DE Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247-9.
20. McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer. 2004;12:454-62.
21. Mclay J, Stewart D, George J, Rore C, Heys S. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol. 2012;68:811-9.
22. Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11:742-52.
23. Molassiotis A, Panteli V, Patiraki E, Ozden G, Platin N, Madsen E, Browall M, Fernandez-Ortega P, Pud D, Margulies A. Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract. 2006;12:34-9.
24. Rotblatt M, Ziment I. Evidence-based herbal medicine. Philadelphia: Hanley & Belfus; 2002.
25. Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, Patanè M, Upton R, Pugliese M, Chimirri S. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res. 2014;28:643-55.
26. Suchard JR, Wallace KL, Gerkin RD. Acute cyanide toxicity caused by apricot kernel ingestion. Ann Emerg Med. 1998;32:742-4.
27. Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos. 2005;33:547-54.
28. Thomsen M, Schmidt M, Vitetta L, Sali A. Do herbs increase the risk of herb-drug interactions for patients with arthritis? Ann Rheumatic Dis. 2005;64:1527-28.
29. Tuna S, Dizdar O, Calis M. The prevalence of usage of herbal medicines among cancer patients. System. 2011;83:32.
30. Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women's views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006;6:40.
31. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer. 2004;90:408-13.
32. WHO. Traditional medicine strategy: 2014-2023 [Online]. World Health Organization; 2013. Available: http://www.who.int/medicines/publications/traditional/trm_strategy14_23/. Accessed 21 Apr 2016.
33. Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf. 2005;4:355-78.
34. Williamson EM, Driver SB, Baxter K, Lee CR. Stockley's Herbal Medicine's Interactions: a guide to the interactions of herbal medicines. London: Pharmaceutical Press; 2013.
35. Wold RS, Lopez ST, Yau CL, Butler LM, Pareo-Tubbeh SL, Waters DL, Garry PJ, Baumgartner RN. Increasing trends in elderly persons' use of non-vitamin, non-mineral dietary supplements and concurrent use of medications. J Am Diet Assoc. 2005;105:54-63.
36. Zachariae R, Johannessen H. A methodological framework for evaluating the evidence for Complementary and Alternative Medicine (CAM) for cancer. Cancers. 2011;3:773-88.
37. Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E, Becker S, Serve H, Huebner J. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin. 2013;139:357-65.